Nurtec ODT wins approval as a preventive treatment of migraine

By Brian Buntz | July 21, 2021

Nurtec ODT Biohaven Pharmaceuticals migraine migraines FDA indicates Biohaven Pharmaceuticals‘ Nurtec ODT for the acute treatment of migraine with or without aura in adults.

The agency recently extended the indication to include the preventive treatment of migraines.

Nurtech is currently the only drug to win FDA approval as both an acute and preventive migraine treatment. The expanded indication has launched the drug into “the next stage of being really disruptive,” according to Biohaven Pharmaceuticals’ CEO Vlad Coric.

Filed Under: Neurological Disease
Tagged With: Biohaven Pharmaceuticals, migraine, migraine headaches, Nurtec

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.